In 2024, the worldwide transport media industry size stood at USD 3,218.9 million, and it is projected to advance at a CAGR of 4.6% over the projection period, to touch USD 4,210.6 million by the end of 2030. This is because of the increasing occurrence of communicable illnesses, like influenza and herpes; rising demand for pre-clinical and diagnostic testing, rising research and development on viral diseases, and the growing count of steps taken by governments to drive the acceptance of testing kits.
Just like the high number of deaths from influenza (around 400,000 in 2022) and the millions suffering from herpes (around 4 billion), the rise of infectious diseases means more people need diagnosis and treatment. This, in turn, fuels the market for tools used in this process.
To keep samples safe during travel from collection to testing, scientists developed special transport media. These can be adjusted depending on the suspected germ. The COVID-19 pandemic, with its massive increase in testing, is a prime example of how this market boomed.
After all, accurate tests rely on high-quality samples, and that means proper storage and transport before reaching the lab. Viral transport media became a go-to solution, leading life science and biotech companies to ramp up production of these tools for transporting swabs from patients to diagnostic labs.
Key Insights
- In 2023, the viral transport media category had a share of, 35%.
- This growth can be credited to the sudden outbreak of communicable diseases, like COVID-19 and monkeypox, which generates the need for analysis and testing among diseased individuals.
- World Health Organization issued and executed biosafety lab rules in 2022 for collecting, testing, and handling samples containing the monkeypox virus, including proper transportation using viral transport solutions.
- The rising number of pharmaceutical and biotechnology companies, along with academic research institutes, increases the demand for viral transport solutions.
- Governments are increasing flu awareness through campaigns, emphasizing prevention and early diagnosis, which boosts test numbers.
- Diagnostic laboratories held the largest share due to increased COVID-19 testing demand and setup.
- Virus genome mutations necessitate identifying specific strains, adding pressure on diagnostic labs.
- Increased awareness of diagnostic testing and government support drive market growth.
- WHO projects the elderly population to rise from 1 billion in 2020 to 1.7 billion in 2030, increasing healthcare service demand.
- Infectious diseases are more common in the elderly, escalating diagnostic test volumes.
- North America dominates the market due to high diagnostic test counts, numerous pharma and biotech companies, and a robust healthcare system.
- Rising infectious disease prevalence drives revenue for market players.
- Regional government initiatives for advanced testing solutions contribute to North American market growth.
- In 2020, about 3.5 million people visited U.S. emergency rooms for infectious diseases.
- Numerous market players in the U.S. ensure easy product availability.
- In April 2021, COPAN Diagnostics launched the UniVerse automated molecular specimen preparation instrument in North America.
- The APAC region is expected to grow the fastest due to high infectious disease incidence, especially in China and India.
- A large population with infectious diseases in APAC leads to a high demand for diagnostics.
- Many market players are addressing the unmet diagnostic needs in APAC.
Comments